Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.

08.25.2022

Mycovia Pharmaceuticals’ Phase 3 ultraVIOLET Study Evaluating the Efficacy and Safety of VIVJOA™ (oteseconazole) in Women with Recurrent Vulvovaginal Candidiasis (RVVC) Published in the American Journal of Obstetrics and Gynecology

Download PDF

08.02.2022

Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022 IDSOG Annual Meeting

Download PDF

07.26.2022

Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) in NEJM Evidence

Download PDF

07.18.2022

Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

Download PDF

06.22.2022

Mycovia Pharmaceuticals Announces Positive New Clinical Findings Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC)

Download PDF
Transforming healthcare together Careers at Mycovia
Working together to transform healthcare Contact Us